Eli Lilly’s Tabalumab Fails over Efficacy in Phase 3 Trial

Eli Lilly’s Tabalumab Fails over Efficacy in Phase 3 Trial

Though, tabalumab's Phase II clinical studies showed success and proved effective, a recent report has revealed that Eli Lilly and Company's human monoclonal antibody failed in terms of meeting efficacy objectives in a next-stage trial.

Of total three Phase 3 rheumatoid arthritis registration studies, one study of the anti-BAFF monoclonal antibody failed, which the researchers say, was totally unexpected. However, the failure is in no way related to safety concerns.

Therefore, as per the findings, patients currently involved in other studies of tabalumab RA would continue the treatment. Lilly would also be working towards the development of additional treatment options so that patients with autoimmune diseases could have an option.

It has been told that the company would evaluate the candidate in two other studies related to Phase 3 RA registration following the open-label extension study as well as other smaller studies. Since, the company is of the belief that it does not have sufficient data to gain U. S. marketing clearance.

"We remain committed to patients with rheumatoid arthritis and lupus and will move rapidly to evaluate the impact of these data on the overall tabalumab clinical development programme", sources quoted vice president for Lilly autoimmune product development Eiry Roberts as saying.


FrenchTribune Specials

Gene variant may define why some drink more or less of coffee

While you may share your love for coffee with large number of people across the world, there is a possibility that consumption level may differ greatly. Why some people could only consume less amount of coffee, while others can take several cups a day is now defined by presence of a gene variant in an individual’s body.

The study that...

Exxon reports 46% decline in First Quarter earning

On Thursday, Exxon reported a 46% decline in earnings in the first quarter, by earning $4.9 billion compared with $9.1 billion in the same quarter a year ago. Exxon's top and bottom lines declined due to lower oil prices.

It was the...

Most Popular

MIT team publishes slow-motion video of sneeze

Lydia Bourouiba, mathematical physicist and head of a...

Report: Google, Facebook, and Twitter are ‘the lifeblood of Daesh’

According to a new report released by the UK Home...

Milk protein helps make edible packaging for food products

Most of the food products come wrapped in plastic...

Poll

Can Greece Come out of Economic Problems: